AFAP1 and esophageal squamous cell carcinoma: Moreover, the pathological complete response rate was 19.8%, the partial response rate was 40.7%, no response rate was 37.7%, and progressive disease response was 1.8%, suggesting the strong hindrance property of lncRNA AFAP1-AS1 in conferring the chemotherapy in ESCC management [58] (Table 1).